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IntroductIon
Obesity is known to increase the risk of cardiovascular dis-
ease (CVD). However, we have recently shown that a sub-
stantial proportion (~30%) of obese US adults do not have 
the clustering of cardiometabolic abnormalities commonly 
associated with obesity including hypertension, dyslipidemia, 
and elevated levels of fasting glucose, insulin resistance, and 
systemic inflammation (1). Two prior studies suggest that 
obesity may increase the risk for CVD only among persons 
with hypertension, dyslipidemia, or type 2 diabetes (2,3). 
Additionally, new research suggests that the cardiovascu-
lar risk reduction of weight loss may  differ in obese per-
sons with vs. without cardiometabolic disturbances (4,5). 
Therefore, examination of the CVD risks associated with 
obesity independent of the cardiometabolic disturbances 
which often, but not always, accompany it is of consider-
able public health and clinical importance. Previous studies 
of the independent CVD risks associated with  obesity have 
provided  contradictory evidence (2,3,6–13), and have largely 
failed to directly examine whether CVD risk is  elevated 
when obesity is unaccompanied by these cardiometabolic 
disturbances. Instead, most published studies used statisti-
cal adjustment to account for the effects of metabolic sta-
tus. In addition, despite that abdominal obesity is known 
to confer greater risk of CVD than BMI-measured obesity, 
very few prior studies have addressed whether abdominal 
obesity is associated with increased risk of CVD even when 
it is unaccompanied by the cardiometabolic abnormalities 
thought to result from it. Therefore, the purpose of this 
study was to evaluate the independent effects of abdominal 
 obesity and cardiometabolic abnormalities on the risk for 
incident CVD. Three large population-based cohort studies 
of men and women were pooled to obtain sufficient sample 
size and numbers of incident CVD events to assess the risk 
of CVD associated with obesity in those with and without 
cardiometabolic abnormalities, and to statistically evaluate 
whether metabolic status modifies the association between 
obesity and incident CVD.
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It remains unclear whether abdominal obesity increases cardiovascular disease (CVD) risk independent of the 
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metabolic syndrome and diabetes were each associated with a significantly increased risk of CVD (2.12 (1.80, 2.50), 
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The population for these analyses is derived from the pooling of three 
large, limited-access public use databases from the following studies: 
the Framingham Offspring Study (FOS), the Atherosclerosis Risk in 
Communities Study (ARIC), and the Cardiovascular Health Study 
(CHS). Informed consent and appropriate institutional review board 
approval was obtained by each center for the three studies.
The FOS was initiated in 1971, and recruited 5,124 men and women 
aged 5–70 years who were children or spouses of participants in the 
Framingham Heart Study. As the FOS did not measure waist circumfer-
ence until the 4th examination, this examination was used as the base-
line visit for the current pooling of data. ARIC recruited 15,732 men 
and women aged 45–64 years in 1987–1989, and CHS initially recruited 
5,201 participants aged ≥65 years in 1989–1990 using Medicare eligibility 
files. In 1992, an additional 687 black participants were recruited. Details 
regarding recruitment and study procedures for each of the three studies 
have been published previously (14–16).
Pooling of the three longitudinal databases resulted in a data set with 
26,744 individuals. Exclusion criteria from the pooled data set included 
missing age information or baseline age <45 years (total n = 2,277; miss-
ing = 1,198; <45 years = 1,079); BMI values in the underweight range 
(<18.5 kg/m2; n = 163); missing data on waist circumference (n = 85); 
history of CVD (coronary heart disease (CHD), stroke, and peripheral 
vascular disease in all studies and heart failure for CHS and the FOS 
cohorts) at study baseline for ARIC and CHS, and at the original study 
baseline or at any time between baseline and the 4th follow-up visit for the 
FOS (n = 3,158); missing data on the four-level metabolic obesity  variable 
(n = 273), and reported fasting <8 h before the study visit (n = 490), leav-
ing data from 20,298 individuals for these analyses.
Blood pressure, anthropometrics, and questionnaire data
For each of the three studies, blood pressure was measured in the seated 
position after a short rest period and averaged across two readings. BMI 
was calculated as the weight in kilograms divided by height in meters 
squared, and categorized as normal weight (BMI <25 kg/m2), overweight 
(BMI 25.0–29.9 kg/m2), or obese (BMI ≥30 kg/m2). Waist circumference 
was measured at the level of the umbilicus while the participant was 
standing, among all three studies. Abdominal obesity was defined as 
waist circumference >102 cm for men and >88 cm for women. Smoking 
and alcohol intake were assessed by questionnaire in each study. As the 
amount of alcohol consumed was not assessed identically across studies, 
participants were coded as current drinkers or not.
Laboratory measurements
Blood samples were obtained after an ≥8-h fast in each study. Laboratory 
methods have been previously reported for all three studies (17–22). Of 
relevance to these analyses, glucose was measured in serum with a Kodak 
Ektachem E-700 (Eastman Kodak, Rochester, NY) among CHS partici-
pants and by a hexokinase/glucose-6-phosphate dehydrogenase method 
among ARIC participants, and in plasma with a hexokinase  reagent kit 
(A-gent glucose test; Abbott, South Pasadena, CA) among FOS par-
ticipants. In all three studies, plasma triglycerides and high-density 
lipoprotein-cholesterol were measured enzymatically (high-density 
lipoprotein-cholesterol after precipitation of low- and very-low-
 density lipoproteins with dextran sulfate–magnesium ions sulfate).
Metabolic syndrome and diabetes definitions
Metabolic syndrome components were defined according to the 
National Cholesterol Education Program’s Adult Treatment Panel III 
(ATP III) revised recommendations (23): (i) fasting serum or plasma 
glucose ≥100 mg/dl, (ii) fasting serum triglycerides ≥150 mg/ dl, 
(iii) fasting serum high-density lipoprotein-cholesterol <40 mg/dl 
for men and <50 mg/dl for women, and (iv) systolic/diastolic blood 
pressure ≥130/85 mm Hg or self-reported use of antihypertensive 
medications. The waist circumference criterion was not included as 
a metabolic syndrome component as it was used to define obesity. 
Diabetes was defined as a fasting serum or plasma glucose ≥126 mg/ dl 
or  self-reported use of antidiabetes medications. Participants were 
categorized into one of four metabolic abnormality groups: (i) no 
metabolic syndrome components or diabetes (“normal” metabo-
lism), (ii) 1–2 metabolic syndrome components and no diabetes (1–2 
 components), (iii) ≥3 metabolic syndrome components and no diabe-
tes (metabolic syndrome), and (iv) diabetes (diabetes).
cVd event ascertainment and follow-up time determination
To ensure consistency of event reporting across the three studies, these 
analyses are limited to probable and definite fatal and nonfatal CHD 
and stroke. In all three studies, CHD was defined as myocardial infarc-
tion, silent myocardial infarction, or CHD death and stroke included 
both hemorrhagic and ischemic subtypes. Event ascertainment has 
been previously reported for all studies (24–27). Briefly, each study 
obtained medical record data through chart abstraction for use in event 
classification, and utilized an adjudication committee to determine final 
event classification. Among all three studies, data abstracted for CHD 
determination included cardiac pain, electrocardiogram findings, and 
 cardiac enzymes, and for stroke determination neurological evalua-
tions, imaging studies, and pathology reports. Specific algorithms for 
event determination were similar, though not identical for all three 
studies, with the exception of myocardial infarction determination, for 
which CHS adopted the ARIC protocol identically.
As each of the three studies varied in the length of available follow-up, 
these analyses are limited to 9 years of follow-up to ensure adequate 
sample size throughout. Follow-up time for analyses of CVD (CHD 
and stroke considered together) was calculated as the time between the 
baseline visit (visit 4 for the FOS) and the first CHD or stroke event, or 
between the baseline visit and the last known contact with the participant 
for those without events.
statistical methods
The distributions of demographic, anthropometric, and laboratory 
 variables were compared across both abdominal obesity and metabolic 
status groupings using χ2-tests for categorical variables and Kruskal–
Wallis or Mann–Whitney U tests for continuous variables. Failure 
curves were generated using the Kaplan–Meier method for the eight 
metabolic categories (i.e., abdominal obesity crossclassified by meta-
bolic abnormality grouping).
After initial adjustment for demographic factors, smoking status, and 
alcohol intake, the independent effects of abdominal obesity and meta-
bolic status on the risks of CVD, CHD, and stroke were examined by 
further adjustment of the Cox proportional hazard ratios (HRs) associ-
ated with abdominal obesity for metabolic status grouping; and further 
adjustment of the Cox proportional HRs associated with metabolic status 
grouping for abdominal obesity. A two-stage approach was used for all 
Cox proportional hazards regression modeling. First, study-specific HRs 
and 95% confidence intervals of each outcome were calculated. Pooled 
HRs were then calculated by combining the study-specific HRs, weighted 
by the inverse of their variance, using a random effects model. For CHD 
event analyses, individuals whose first event was a stroke were censored 
at the time of their stroke, whereas for stroke analyses, individuals whose 
first event was a CHD event were censored at the time of their CHD event. 
There were two cases where a CHD event and stroke event occurred 
on the same day, and these individuals were counted only once in total 
CVD analyses. Statistical interactions between abdominal obesity and 
metabolic status on the risk of CVD were tested via multiplicative inter-
action terms (i.e., abdominal obesity group × metabolic status and waist 
circumference, modeled as a continuous variable, × metabolic status). 
To ensure that covariability between abdominal obesity and metabolism 
was not affecting resulting estimates, analyses of abdominal obesity were 
stratified by metabolic status and vice versa. The proportional hazards 
assumption was evaluated by Schoenfeld residuals in all Cox models, 
and was not violated.
Sensitivity analyses were conducted by assessing the outcomes of fatal 
and nonfatal events, separately, by assessing outcomes in subgroups 
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defined by age (45–64 years and ≥65 years) and sex, and using BMI 
groups (<25 kg/m2, 25–29.9 kg/m2, and ≥30 kg/m2) in place of abdomi-
nal obesity. Sensitivity analyses were also performed excluding events 
within the first 2 years in an attempt to remove the influence of subclinical 
disease at baseline on the results, and incorporating cholesterol-lowering 
medication use into the high-density lipoprotein-cholesterol criterion of 
the metabolic syndrome definition (n = 637). This lead to an additional 65 
people recategorized as having 1–2 components, and 93 people recatego-
rized as having metabolic syndrome. All analyses were conducted using 
STATA, version 10 (StataCorp, College Station, TX).
resuLts
The average follow-up was 8.3 (s.d. 1.9) years, and over this 
time there were a total of 1,766 fatal or nonfatal incident CVD 
events (1,118 CHD events and 648 stroke events). Because two 
individuals had a CHD event and a stroke simultaneously, the 
number of events used for the combined CVD analyses was 
1,764. Compared to nonobese individuals, those with abdomi-
nal obesity were more likely to be 45–64 years of age, women, 
African Americans, less educated, never smokers, never or 
former drinkers, to have metabolic syndrome or diabetes, 
and to have worse levels of metabolic syndrome components 
(Table 1). Compared to individuals without any metabolic 
syndrome components or diabetes, individuals with the meta-
bolic syndrome or diabetes were older, and more likely to be 
men, African Americans, never smokers, less educated, never 
or former drinkers, obese, and to have worse levels of CVD 
risk factors (Table 2).
When abdominal obesity and metabolic categories were con-
sidered in combination, three groups of failure curves emerged 
corresponding to the metabolic categories (0 risk factors, 1–2 
components or metabolic syndrome, and diabetes) (Figure 1).
After adjustment for age, sex, race, education, smoking 
 status, and alcohol intake, abdominal obesity was associated 
with a 33% increased risk of total CVD (CHD and stroke) in 
pooled analyses (Table 3). However, after further adjustment 
for metabolic status, abdominal obesity was no longer signifi-
cantly associated with increased risk of CVD. Metabolic syn-
drome and diabetes were associated with 100–400% increased 
risk of incident CVD events after initial adjustment for age, sex, 
race, education, smoking status, and alcohol intake, as well as 
after further adjustment for abdominal obesity. HRs for CHD 
and stroke showed similar patterns and effect magnitudes.
In stratified analyses, abdominal obesity was not signifi-
cantly associated with an increased risk of incident CVD for 
participants with normal metabolism, metabolic syndrome 
or  diabetes (Figure 2). However, an association was present 
between abdominal obesity and increased risk of incident 
CVD for those with 1–2 metabolic components. Among both 
nonobese and abdominally obese individuals, participants 
with 1–2 metabolic components, metabolic syndrome, and 
diabetes had an increased risk of incident CVD compared to 
those with normal metabolism. Results were similar when 
waist circumference was modeled as a continuous variable 
(data not shown). There was no significant statistical interac-
tion between metabolic status and either abdominal obesity or 
waist circumference expressed as a continuous variable on the 
risks of CVD (P = 0.48 and P = 0.49, respectively).
sensitivity analyses
The results were markedly similar after excluding events that 
occurred within the first 2 years of follow-up (data not shown). 
Additionally, the associations were also similar when analyses 
were conducted stratified by sex, age group, and by fatal vs. 
nonfatal event status, and considering cholesterol-lowering 
medication use in the metabolic syndrome definition (data 






(n = 9,941) P value
Age group, %
 45–64.9 years 7,858 (75.9%) 7,740 (77.9%) 0.001
 ≥65 years 2,499 (24.1%) 2,201 (22.1%)
Sex, % <0.001
 Women 4,590 (44.3%) 6,826 (68.7%)
 Men 5,767 (55.7%) 3,115 (31.3%)
Race, % <0.001
 White 8,744 (84.4%) 7,536 (75.8%)




 ≤High school 5,229 (50.5%) 5,966 (60.0%)
 >High school 5,128 (49.5%) 3,975 (40.0%)
Cigarette smoking, %
 Never 3,931 (38.6%) 4,570 (46.4%) <0.001
 Current 2,491 (24.5%) 1,994 (20.3%)




 Never or Former 3,801 (36.8%) 4,868 (49.2%)
 Current 6,541 (63.3%) 5,032 (50.8%)
Cardiometabolic status, %
 Normal 2,752 (26.6%) 1,159 (11.7%) <0.001
 1–2 Components 5,773 (55.7%) 4,941 (49.7%)
  Metabolic 
syndrome
1,249 (12.1%) 2,322 (23.4%)
Diabetes 583 (5.6%) 1,519 (15.3%)
Systolic BP, mm Hg 123.4 (20.4) 127.6 (19.8) <0.001
Diastolic BP, mm Hg 73.2 (11.4) 74.9 (11.1) <0.001
HDL cholesterol, 
mmol/l
1.41 (0.45) 1.30 (0.40) <0.001
Triglycerides, 
mmol/la
1.12 (0.82–1.57) 1.40 (1.02–1.98) <0.001
Glucose, mmol/la 5.34 (5.02–5.72) 5.61 (5.22–6.20) <0.001
Waist 
circumference, cm
86.6 (9.0) 104.4 (10.7) <0.001
Values in table are n (%) or mean (standard deviation) unless otherwise 
indicated.
BP, blood pressure; HDL, high-density lipoprotein.
aValues are median (interquartile range).
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not shown). Finally, all analyses were repeated using BMI 
categories (normal weight, overweight, obese) rather than 
waist circumference, and analyses were also similar (data not 
shown). When analyses were conducted for each of the three 
studies separately, a significant effect of abdominal obesity on 
risk for CVD (HR for total CVD events 1.17; 95% confidence 
interval 1.01–1.37) was present after adjustment for meta-
bolic status in the ARIC study, but not in the CHS or FOS 
(HR 1.01 (0.87–1.18) and 1.06 (0.73–1.54) respectively) (see 
Supplementary Table S1 online). However, this difference 
between studies was not statistically significant, as indicated 
by a nonsignificant study × abdominal obesity interaction 
term (P = 0.52). Similar to the pooled analysis, within each 
of the three studies, abdominal obesity was not statistically 
significantly associated with increased risk of CVD within 
metabolic status categories, but 1–2 metabolic components, 
metabolic syndrome, and diabetes were each associated 
with incident CVD events among both abdominally obese 
table 2 Baseline characteristics of study participants by metabolic syndrome and diabetes status
Normal (n = 3,911)






(n = 2,102) P value
Age group, %
 45–64.9 years 3,354 (85.8%) 8,119 (75.8%) 2,670 (74.8%) 1,455 (69.2%) <0.001
 ≥65 years 557 (14.2%) 2,595 (24.2%) 901 (25.2%) 647 (30.8%)
Sex, %
 Women 2,589 (66.2%) 5,941 (55.5%) 1,740 (48.7%) 1,146 (54.5%) <0.001
 Men 1,322 (33.8%) 4,773 (44.6%) 1,831 (51.3%) 956 (45.5%)
Race, %
 White 3,362 (86.0%) 8,479 (79.1%) 3,019 (84.5%) 1,420 (67.6%) <0.001
 African American 549 (14.0%) 2,235 (20.9%) 552 (15.5%) 682 (32.5%)
≥High school education, %
 <High school 1,813 (46.4%) 5,828 (54.4%) 2,161 (60.5%) 1,393 (66.3%) <0.001
 ≥High school 2,098 (53.6%) 4,886 (45.6%) 1,410 (39.5%) 709 (33.7%)
Cigarette smoking, %
 Never 1,769 (45.9%) 4,432 (42.0%) 1,357 (38.4%) 943 (45.3%) 0.001
 Current 821 (21.3%) 2,412 (22.8%) 850 (24.1%) 402 (19.3%)
 Former 1,268 (32.9%) 3,720 (35.2%) 1,324 (37.5%) 737 (35.4%)
Alcohol consumption, %
 Never or former 1,391 (35.7%) 4,455 (41.7%) 1,557 (43.7%) 1,266 (60.5%) <0.001
 Current 2,511 (64.4%) 6,230 (58.3%) 2,004 (56.3%) 828 (39.5%)
Abdominal obesity, %
 Nonobese 2,752 (70.4%) 5,773 (53.9%) 1,249 (35.0%) 583 (27.7%) <0.001
 Obese 1,159 (29.6%) 4,941 (46.1%) 2,322 (65.0%) 1,519 (72.3%)
BMI group, %
 Normal weight 2,239 (57.3%) 3,850 (36.0%) 615 (17.2%) 338 (16.1%) <0.001
 Overweight 1,318 (33.7%) 4,560 (42.6%) 1,610 (45.1%) 807 (38.5%)
 Obese 353 (9.0%) 2,299 (21.5%) 1,343 (37.6%) 954 (45.5%)
Systolic BP, mm Hg 110.8 (10.4) 126.6 (20.3) 132.9 (19.0) 134.2 (21.5) <0.001
Diastolic BP, mm Hg 68.5 (8.0) 74.7 (11.5) 77.3 (11.1) 75.4 (11.9) <0.001
HDL cholesterol, mmol/l 1.63 (0.39) 1.40 (0.42) 1.03 (0.26) 1.18 (0.36) <0.001
Triglycerides, mmol/la 0.90 (0.70–1.15) 1.19 (0.89–1.54) 2.06 (1.73–2.60) 1.68 (1.18–2.46) <0.001
Glucose, mmol/la 5.11 (4.86–5.29) 5.40 (5.08–5.77) 5.83 (5.56–6.16) 8.38 (7.22–11.38) <0.001
Waist circumference, cm 87.7 (11.7) 94.5 (12.6) 101.2 (11.8) 103.9 (13.0) <0.001
BMI, kg/m2 24.9 (3.8) 27.0 (4.6) 29.2 (4.8) 30.1 (5.4) <0.001
Values in table are n (%) or mean (standard deviation) unless otherwise indicated.
BP, blood pressure; HDL, high-density lipoprotein.
aValues are median (interquartile range).
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and nonobese participants (see Supplementary Table S2 
online).
dIscussIon
The present analyses of data pooled from three large cohort 
studies showed that after accounting for metabolic status, 
abdominal obesity was not associated with a significantly 
increased risk for CHD or stroke in nearly every case, the one 
exception being among those with 1–2 metabolic components. 
However, the presence of metabolic syndrome components, 
metabolic syndrome, or diabetes were each associated with 
~2–5 times increased risk for CHD or stroke over an aver-
age follow-up of 8 years, even after accounting for abdominal 
obesity.
In this study, we assessed the independent effects of abdomi-
nal obesity and metabolism by two different methods. After 
statistical adjustment for metabolic status, abdominal obesity 
was not associated with a statistically significantly increased 
risk for CVD. Similarly, stratified analyses of the association 
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Years of follow-up
Nonobese, diabetes (n = 583)
(Figure key lists categories in order of failure lines) 
Abdominally obese, diabetes (n = 1,519)
Nonobese, metabolic syndrome (n = 1,249)
Abdominally obese, metabolic syndrome (n = 2,322)
Nonobese, 1–2 risk factors (n = 5,773)
Abdominally obese, 1–2 risk factors (n = 4,941)
Nonobese, normal metabolism (n = 2,752)
Abdominally obese, normal metabolism (n = 1,159)
Figure 1 Kaplan–Meier plot of cardiovascular disease event rates by the eight joint obesity/metabolic abnormality categories.
Risk of CVD associated with abdominal obesity













Risk of CVD associated with metabolic abnormalities





























Figure 2 Forest plot of pooled adjusteda hazard ratios (95% confidence intervals) for incident CVD events associated with metabolic status stratified 
by abdominal obesity (top) and associated with abdominal obesity stratified by metabolic status (bottom). CVD, cardiovascular disease. aAdjusted for 
age, sex, race, education, smoking status, and alcohol intake.
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group showed that abdominal obesity was not significantly 
associated with CVD among those with 0 components, meta-
bolic syndrome, or diabetes. However, those with 1–2 meta-
bolic syndrome components had an increased risk for CVD 
associated with abdominal obesity that was statistically sig-
nificant. Although this latter result raises the possibility that 
abdominal obesity may increase the risk of CVD  independent 
of metabolic abnormalities, this increased risk was modest (HR 
1.17) compared with the increased risk associated with varying 
degrees of metabolic abnormalities (HRs ranging from 1.97 to 
4.61), and was not found among those with 0 components, 
metabolic syndrome, or diabetes. Figure 2 presents a strik-
ing visual illustration of the strong risks of CVD associated 
with metabolic abnormalities compared with the lack of an 
association between abdominal obesity and CVD. Therefore, 
these analyses support previous studies showing that the risk 
of CVD commonly associated with obesity is largely driven by 
concomitant metabolic abnormalities (2,3,6–8).
The current results contradict some prior studies which have 
suggested the possibility that metabolic status may modify 
the obesity–CVD relationship (2,3). In the Aerobics Center 
Longitudinal Study (ACLS), abdominal obesity was associ-
ated with incident CVD events over 10–11 years of follow-up 
among middle-aged men who had hypertension, dyslipidemia, 
or diabetes but not among those without these factors (2). 
Similar results were reported for obesity defined by BMI among 
 middle-aged women in the Women’s Health Study (3). However, 
in our stratified analyses, the HR for CVD events associated 
with abdominal obesity was 1.03 among those with metabolic 
syndrome and 0.94 among those with diabetes, suggesting that 
even in the presence of multiple metabolic abnormalities or 
diabetes, abdominal obesity was not significantly associated 
with elevated risk of CVD. The interaction term (abdominal 
 obesity × metabolic status) was not statistically significant, fur-
ther confirming the lack of effect modification in this study.
BMI-defined obesity and abdominal obesity have been found 
to impart significantly increased risk of CVD independent of 
standard risk factors and diabetes in some studies (9–11,13). 
Notably, significant associations with obesity appear to be 
more frequently observed in studies of longer duration, raising 
the possibility that obesity increases long-term (20–25 years) 
risk of CVD, perhaps due to enhanced subclinical athero-
sclerosis in obese individuals. Obese, metabolically healthy 
individuals have been shown to have impaired endothelial dys-
function and greater carotid intima–media thickness (ref. 28 
and U. Khan, D. Wang, and R. Thurston et al., unpublished 
table 3 Pooled hrs (95% cIs) for incident cVd events associated with abdominal obesity and metabolic status
CHD Stroke Total CVD
Adjusted HR (95% CI) Adjusted HR (95% CI) Adjusted HR (95% CI)
Abdominal obesity
 Model 1a
  Nonobese (reference) 1.00 1.00 1.00
  Obese 1.40 (1.10–1.79) 1.18 (1.00–1.39) 1.33 (1.09–1.63)
  P value <0.01 0.05 <0.01
 Model 1a + adjustment for metabolic status grouping
  Nonobese (reference) 1.00 1.00 1.00
  Obese 1.13 (0.99–1.29) 1.00 (0.85–1.19) 1.09 (0.98–1.20)
  P value 0.06 0.97 0.12
Metabolic status
 Model 1a
  Normal (reference) 1.00 1.00 1.00
  1–2 Components 2.20 (1.70–2.84) 1.84 (1.34–2.52) 2.09 (1.71–2.54)
  Metabolic syndrome 2.92 (1.89–4.53) 1.86 (1.29–2.64) 2.67 (1.79–3.98)
  Diabetes 5.19 (3.22–8.36) 4.20 (2.38–7.40) 5.14 (3.13–7.76)
  P value <0.001 <0.001 <0.001
 Model 1a + adjustment for abdominal obesity
  Normal (reference) 1.00 1.00 1.00
  1–2 Components 2.15 (1.66–2.78) 1.86 (1.31–2.64) 2.05 (1.68–2.50)
  Metabolic syndrome 2.77 (1.90–4.03) 1.86 (1.29–2.68) 2.56 (1.78–3.69)
  Diabetes 4.90 (3.25–7.39) 4.22 (2.35–7.59) 4.91 (3.11–7.76)
  P value <0.001 <0.001 <0.001
CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.
aAdjusted for age, sex, race, education, smoking status, and alcohol intake.
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data). However, all but one of the incident CVD studies with 
long-term  follow-up used statistical adjustment to account for 
metabolic abnormalities, rather than stratification, and none 
accounted for the development of cardiometabolic abnormali-
ties across follow-up. Therefore, it remains unclear whether 
obesity without concomitant metabolic abnormalities is asso-
ciated with elevated long-term risk of CVD.
In stratified analyses, individuals who were abdominally 
obese but did not have any of the metabolic syndrome com-
ponents or diabetes were not at significantly increased risk for 
CHD or stroke over an average follow-up of 8 years compared 
to similar individuals without obesity. However, stratified anal-
yses also showed that individuals without abdominal obesity 
had a substantially increased risk for CHD or stroke over 8 years 
if they possessed metabolic syndrome components or diabetes 
compared to individuals without these  factors. Similar results 
were found in sensitivity analyses among normal-weight indi-
viduals, as defined by BMI. Therefore, in addition to highlight-
ing the need for risk stratification via assessment of metabolic 
abnormalities among obese individuals, these data suggest that 
the metabolic syndrome may confer an approximate three-
fold increase in risk of incident CVD even in normal-weight 
individuals.
The results of this study must be viewed within the context 
of its limitations. As indicated previously, measurement proto-
cols were not identical for certain laboratory and questionnaire 
data across the three studies. However, we analyzed data in 
two stages and present both study-specific and pooled results. 
Results were similar for each of the three studies. There were 
insufficient numbers of African Americans to stratify results 
by race. The frequency and extent of assessment of body size 
and metabolic changes across follow-up were not uniform for 
all three studies and comparable data on physical activity was 
not available at baseline for each study, and therefore, these 
could not be taken into account in the statistical analyses. 
Additionally, in order to maintain sufficient numbers of events 
in all three studies across the follow-up period, we were limited 
to 9 years of follow-up. Longer follow-up is needed to examine 
whether the effect of obesity is more pronounced when risk of 
CVD is examined over an extended time frame.
However, this study also has a number of strengths. With 
the large sample size resulting from the pooling of longitudi-
nal databases, substantial numbers of CHD and stroke events 
occurred, permitting the investigation of the independent risks 
of CVD associated with obesity and abnormal metabolism in 
important population subgroups. The large sample size also 
afforded us the power to assess independence of abdominal 
obesity from metabolic status via stratification, as well as to 
formally assess effect modification. Each of the three studies 
pooled in these analyses followed standardized data collection 
protocols for measurement of the variables included here-in, 
and each performed active follow-up for CVD events with for-
mal adjudication of events.
In conclusion, these analyses of individuals from three large, 
longitudinal population-based studies, suggest that the pres-
ence of metabolic abnormalities is a substantially stronger 
predictor than abdominal obesity of incident CHD and stroke 
over an average of 8 years. Although abdominal obesity and 
body size remain important clinical tools for identification of 
individuals likely to possess metabolic abnormalities,  metabolic 
syndrome and diabetes are considerably more important prog-
nostic indicators of CVD risk. These data underscore the need 
for close monitoring and treatment of adverse levels of blood 
pressure, lipids, and glucose even among normal-weight or 
nonobese individuals.
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